GlassScriptPhysician profile
James R Coster
NPI 1730152679
$1,696.27
in general payments reported to CMS, 2019-2025
13 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.37 · 2020: $651 · 2023: $336 · 2024: $233 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $744.25 | 2019-2020 | |
| Boston Scientific Corporation | $165.58 | 2023-2024 | Spaceoar System, Spaceoar Vue System - 10ml |
| Teleflex LLC | $141.66 | 2024-2025 | Barrigel |
| Dendreon Pharmaceuticals LLC | $125.60 | 2023 | Provenge |
| Novocure INC. | $120.24 | 2025 | Optune Lua (Novottf-200t) |
| Mevion_medical_systems_inc | $95.83 | 2023 | Pts250 |
| Progenics Pharmaceuticals, INC. | $87.13 | 2024-2025 | |
| Astellas Pharma US INC | $55.63 | 2024-2025 | Xtandi |
| Abbvie INC. | $49.28 | 2023-2024 | Lupron Depot |
| Myriad Genetic Laboratories, INC. | $44.76 | 2025 | Prolaris |
| Tolmar, INC. | $26.72 | 2025 | Eligard |
| Sumitomo Pharma America, INC. | $22.10 | 2024 | Orgovyx |
| Blue Earth Diagnostics | $17.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Coster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.